Switch theme
Sign up to access all valuation multiples
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
2000
28
Last FY Revenue n/a
LTM EBITDA -$33.3M
$125M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
DiaMedica has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$33.3M.
In the most recent fiscal year, DiaMedica achieved revenue of n/a and an EBITDA of -$26.6M.
DiaMedica expects next 12-month revenue of XXX and NTM EBITDA of XXX
See DiaMedica valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$33.3M | XXX | -$26.6M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$30.9M | XXX | -$26.7M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$29.1M | XXX | -$24.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, DiaMedica's stock price is $4.
DiaMedica has current market cap of $161M, and EV of $125M.
See DiaMedica trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $125M | $161M | XXX | XXX | XXX | XXX | $-0.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, DiaMedica has market cap of $161M and EV of $125M.
DiaMedica's trades at n/a EV/Revenue multiple, and -4.7x EV/EBITDA.
Equity research analysts estimate DiaMedica's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
DiaMedica has a P/E ratio of -5.5x.
See valuation multiples for DiaMedica and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $161M | XXX | $161M | XXX | XXX | XXX |
| EV (current) | $125M | XXX | $125M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -3.8x | XXX | -4.7x | XXX | XXX | XXX |
| EV/EBIT | -4.1x | XXX | -4.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.5x | XXX | -6.6x | XXX | XXX | XXX |
| EV/FCF | -4.5x | XXX | -5.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialDiaMedica's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.0M for the same period.
DiaMedica's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
DiaMedica's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for DiaMedica and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
DiaMedica acquired XXX companies to date.
Last acquisition by DiaMedica was XXXXXXXX, XXXXX XXXXX XXXXXX . DiaMedica acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was DiaMedica founded? | DiaMedica was founded in 2000. |
| Where is DiaMedica headquartered? | DiaMedica is headquartered in United States of America. |
| How many employees does DiaMedica have? | As of today, DiaMedica has 28 employees. |
| Who is the CEO of DiaMedica? | DiaMedica's CEO is Mr. Rick Pauls. |
| Is DiaMedica publicy listed? | Yes, DiaMedica is a public company listed on NAS. |
| What is the stock symbol of DiaMedica? | DiaMedica trades under DMAC ticker. |
| When did DiaMedica go public? | DiaMedica went public in 2007. |
| Who are competitors of DiaMedica? | Similar companies to DiaMedica include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of DiaMedica? | DiaMedica's current market cap is $161M |
| Is DiaMedica profitable? | Yes, DiaMedica is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of DiaMedica? | DiaMedica's last 12 months EBITDA is -$33.3M. |
| What is the current EV/EBITDA multiple of DiaMedica? | Current EBITDA multiple of DiaMedica is -3.8x. |
| What is the current FCF of DiaMedica? | DiaMedica's last 12 months FCF is -$28.1M. |
| What is the current EV/FCF multiple of DiaMedica? | Current FCF multiple of DiaMedica is -4.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
